111 related articles for article (PubMed ID: 27124588)
1. Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas.
Ravishankar S; Nagarajan P; Curry JL; Tetzlaff MT; Ivan D; Torres-Cabala CA; Aung PP; Prieto VG
J Cutan Pathol; 2016 Aug; 43(8):722-4. PubMed ID: 27124588
[No Abstract] [Full Text] [Related]
2. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
[TBL] [Abstract][Full Text] [Related]
3. Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.
Marin C; Beauchet A; Capper D; Zimmermann U; Julié C; Ilie M; Saiag P; von Deimling A; Hofman P; Emile JF
Arch Pathol Lab Med; 2014 Jan; 138(1):71-5. PubMed ID: 23651150
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
5. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
6. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
[TBL] [Abstract][Full Text] [Related]
7. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
10. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
[TBL] [Abstract][Full Text] [Related]
12. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
13. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J
Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584
[TBL] [Abstract][Full Text] [Related]
14. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma.
Rushton S; Burghel G; Wallace A; Nonaka D
Histopathology; 2016 Sep; 69(3):524-6. PubMed ID: 26987976
[No Abstract] [Full Text] [Related]
16. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
[TBL] [Abstract][Full Text] [Related]
17. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
18. Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry.
Dinges HC; Capper D; Ritz O; Brüderlein S; Marienfeld R; von Deimling A; Möller P; Lennerz JK
Appl Immunohistochem Mol Morphol; 2015; 23(5):382-8. PubMed ID: 25611237
[TBL] [Abstract][Full Text] [Related]
19. Controversies in Intrapatient Melanoma BRAFV600E Mutation Status.
Riveiro-Falkenbach E; Santos-Briz A; Ríos-Martín JJ; Rodríguez-Peralto JL
Am J Dermatopathol; 2017 Apr; 39(4):291-295. PubMed ID: 28323782
[TBL] [Abstract][Full Text] [Related]
20. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
